Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
GlucoTrack Inc (GCTK)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
03/27/2025: GCTK (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Analysis of Past Performance
Type Stock | Historic Profit 10.09% | Avg. Invested days 36 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  2.0 |
| Profits based on simulation | Last Close 03/27/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 2.21M USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) 5990420 | Beta -0.3 | 52 Weeks Range 0.15 - 99.00 | Updated Date 04/6/2025 |
52 Weeks Range 0.15 - 99.00 | Updated Date 04/6/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -68.44 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -204.31% | Return on Equity (TTM) -1943.32% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -3138712 | Price to Sales(TTM) - |
Enterprise Value -3138712 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -1.01 | Shares Outstanding 13162400 | Shares Floating 281527 |
Shares Outstanding 13162400 | Shares Floating 281527 | ||
Percent Insiders 2.53 | Percent Institutions 0.43 |
Analyst Ratings
Rating - | Target Price - | Buy - | Strong Buy - |
Buy - | Strong Buy - | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
GlucoTrack Inc
Company Overview
History and Background
GlucoTrack, Inc. (GALT) is a bio-sensor technology company focusing on the design, development, and commercialization of novel technologies for people with diabetes. The company aims to provide a non-invasive alternative for glucose monitoring.
Core Business Areas
- Non-invasive Glucose Monitoring: GlucoTrack develops and commercializes a non-invasive glucose monitoring device. The device uses a sensor clipped to the earlobe to measure glucose levels without drawing blood.
Leadership and Structure
Details of the leadership and organizational structure are not publicly available in detail, since it is a small cap.
Top Products and Market Share
Key Offerings
- GlucoTrack Model DF-F: A non-invasive glucose monitoring device that uses ultrasound, electromagnetic and thermal technologies to measure glucose levels through a sensor clipped to the earlobe. Market share data is limited due to the product's niche status and limited adoption. Competitors: Traditional blood glucose meters from companies like Abbott (ABT), Dexcom (DXCM), and Medtronic (MDT), as well as other emerging non-invasive glucose monitoring technologies.
Market Dynamics
Industry Overview
The glucose monitoring market is a large and growing market, driven by the increasing prevalence of diabetes globally. The market is characterized by continuous technological innovation, including the development of continuous glucose monitors (CGMs) and non-invasive solutions.
Positioning
GlucoTrack aims to position itself as a provider of non-invasive glucose monitoring solutions, targeting individuals who prefer alternatives to traditional blood glucose meters. However, it faces challenges from established players and emerging CGM technologies.
Total Addressable Market (TAM)
The global diabetes care devices market is expected to reach hundreds of billions of USD. GlucoTrack is positioned to capture a niche segment focused on non-invasive solutions, but its success depends on product adoption and market acceptance.
Upturn SWOT Analysis
Strengths
- Non-invasive glucose monitoring technology
- Potential for increased patient comfort and convenience
Weaknesses
- Limited clinical data compared to established blood glucose meters and CGMs
- Small Market capitalization
- Limited commercial traction and market penetration
- Reliance on a single product
Opportunities
- Growing demand for non-invasive glucose monitoring solutions
- Potential for partnerships with diabetes care providers and technology companies
- Expansion into new markets
Threats
- Competition from established blood glucose meter and CGM manufacturers
- Regulatory hurdles for non-invasive medical devices
- Potential for technological advancements from competitors
- Risk of product recalls or safety concerns
Competitors and Market Share
Key Competitors
- ABT
- DXCM
- MDT
Competitive Landscape
GlucoTrack faces significant challenges from larger, established competitors with greater resources and market presence. Its advantage lies in its non-invasive technology, but it needs to overcome challenges in terms of clinical validation and market acceptance.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been limited due to challenges in market adoption and commercialization.
Future Projections: Future growth projections are uncertain and depend on successful product launches and market penetration.
Recent Initiatives: Recent initiatives may include efforts to secure regulatory approvals, expand distribution partnerships, and develop new product features.
Summary
GlucoTrack's non-invasive glucose monitoring technology is promising, but the company faces substantial challenges. It has limited commercial traction and faces competition from established players. Financial performance is weak and the company relies on ongoing capital raises. Future success depends on successful product launches and increased market adoption.
Similar Companies
ABT
Abbott Laboratories
ABT
Abbott Laboratories
DXCM
DexCom Inc
DXCM
DexCom Inc
MDT
Medtronic PLC
MDT
Medtronic PLC
Sources and Disclaimers
Data Sources:
- Company filings
- Market research reports
- Financial news sources
Disclaimers:
This analysis is based on publicly available information and is not financial advice. Investment decisions should be made after conducting thorough due diligence and consulting with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About GlucoTrack Inc
Exchange NASDAQ | Headquaters Rutherford, NJ, United States | ||
IPO Launch date 2013-04-25 | CEO, President & Director Mr. Paul V. Goode Ph.D. | ||
Sector Healthcare | Industry Medical Instruments & Supplies | Full time employees 6 | Website https://glucotrack.com |
Full time employees 6 | Website https://glucotrack.com | ||
GlucoTrack, Inc., a medical device company, focused on the design, development, and commercialization of novel technologies for people with diabetes in the United States. It develops GlucoTrack, a noninvasive glucose monitoring device that helps people with diabetes and pre-diabetics to obtain blood glucose level readings without the pain. The company was formerly known as Integrity Applications, Inc. and changed its name to GlucoTrack, Inc. in November 2021. GlucoTrack, Inc. was founded in 2001 and is based in Rutherford, New Jersey.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.